ARTESUNATE

/static/temp/default.svg Search structure
Synonyms
Status
Molecule Category Free-form
ATC P01BE03
UNII 60W3249T9M

Structure

InChI Key FIHJKUPKCHIPAT-AHIGJZGOSA-N
Smiles C[C@H]1[C@H](OC(=O)CCC(=O)O)O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]1[C@@]24OO3
InChI
InChI=1S/C19H28O8/c1-10-4-5-13-11(2)16(23-15(22)7-6-14(20)21)24-17-19(13)12(10)8-9-18(3,25-17)26-27-19/h10-13,16-17H,4-9H2,1-3H3,(H,20,21)/t10-,11-,12+,13+,16-,17-,18-,19-/m1/s1

Physicochemical Descriptors

Property Name Value
Molecular Formula C19H28O8
Molecular Weight 384.43
AlogP 2.6
Hydrogen Bond Acceptor 7.0
Hydrogen Bond Donor 1.0
Number of Rotational Bond 4.0
Polar Surface Area 100.52
Molecular species ACID
Aromatic Rings 0.0
Heavy Atoms 27.0
Assay Description Organism Bioactivity Reference
In vitro antimalarial activity against chloroquine-resistant Plasmodium falciparum K1 Plasmodium falciparum 0.0006 ug.mL-1
In vitro antimalarial activity against chloroquine-sensitive Plasmodium falciparum 3D7 Plasmodium falciparum 0.0002 ug.mL-1
In vitro inhibition of chloroquine-resistant Plasmodium falciparum K1 Plasmodium falciparum 0.0013 ug.mL-1
In vitro concentration of compound required to inhibit LPS-induced B cell proliferation to 50% in BALB/c mice Mus musculus 989.0 nM
In vitro inhibition of chloroquine-sensitive Plasmodium falciparum NF54 Plasmodium falciparum 0.0016 ug.mL-1
Antimalarial activity against Plasmodium falciparum K1 Plasmodium falciparum 0.0013 ug.mL-1
Antimalarial activity against Plasmodium falciparum NF54 Plasmodium falciparum 0.0016 ug.mL-1
Antimalarial activity against Plasmodium falciparum NF54 within 48 hrs Plasmodium falciparum 4.2 nM
Antimalarial activity against chloroquine-resistant Plasmodium falciparum FcB1 Plasmodium falciparum 2.3 nM
Antimalarial activity against chloroquine-resistant Plasmodium falciparum FcM29 Plasmodium falciparum 1.6 nM
Antimalarial activity against chloroquine-resistant Plasmodium falciparum W2 gametocytes (stage 2 & 3) Plasmodium falciparum 72.0 nM
Antimalarial activity against chloroquine-resistant Plasmodium falciparum W2 gametocytes (stage 4 & 5) Plasmodium falciparum 108.0 nM
Antimalarial activity against chloroquine-resistant Plasmodium falciparum W2 asexual gametocytes Plasmodium falciparum 6.0 nM
Antiparasitic activity against chloroquine-sensitive Plasmodium falciparum by [3H]hypoxanthine incorporation Plasmodium falciparum 2.3 nM
Antimalarial activity against chloroquine-resistant Plasmodium falciparum K1 assessed as inhibition of parasite growth after 48 hrs by [3H]hypoxanthine reuptake assay Plasmodium falciparum K1 2.46 nM
Antimalarial activity against chloroquine-sensitive Plasmodium falciparum IMTVo1 infected in erythrocytes after 48 hrs by [3H]hypoxanthine incorporation assay Plasmodium falciparum 3.0 nM
Antimalarial activity against chloroquine-sensitive Plasmodium falciparum IMT10500 infected in erythrocytes after 48 hrs by [3H]hypoxanthine incorporation assay Plasmodium falciparum 3.8 nM
Antimalarial activity against chloroquine-sensitive Plasmodium falciparum IMTL1 infected in erythrocytes after 48 hrs by [3H]hypoxanthine incorporation assay Plasmodium falciparum 1.7 nM
Antimalarial activity against chloroquine-sensitive Plasmodium falciparum PA infected in erythrocytes after 48 hrs by [3H]hypoxanthine incorporation assay Plasmodium falciparum 2.0 nM
Antimalarial activity against chloroquine-sensitive Plasmodium falciparum FCR3 infected in erythrocytes after 48 hrs by [3H]hypoxanthine incorporation assay Plasmodium falciparum FCR-3/Gambia 2.1 nM
Antimalarial activity against chloroquine-sensitive Plasmodium falciparum FCM29 infected in erythrocytes after 48 hrs by [3H]hypoxanthine incorporation assay Plasmodium falciparum 1.9 nM
Antimalarial activity against chloroquine-sensitive Plasmodium falciparum IMT K2 infected in erythrocytes after 48 hrs by [3H]hypoxanthine incorporation assay Plasmodium falciparum 1.8 nM
Antimalarial activity against Plasmodium berghei ANKA infected Swiss CD1 mice (Mus musculus) assessed as reduction of parasitemia at 30 mg/kg, perorally administered after 3 hrs of infection for 3 days measured on day 4 relative to control Plasmodium berghei 100.0 %
Antimalarial activity against Plasmodium berghei ANKA infected NMRI mice (Mus musculus) assessed as reduction of parasitemia at 10 mg/kg, perorally 4 consecutive doses for 3 days measured on day 4 by FACS analysis Plasmodium berghei 98.0 %
Antimalarial activity against chloroquine-resistant Plasmodium falciparum K1 infected in human A+ erythrocytes assessed as [3H]hypoxanthine incorporation by semiautomated micro dilution assay Plasmodium falciparum K1 0.0013 ug.mL-1
Antimalarial activity against chloroquine-sensitive Plasmodium falciparum NF54 infected in human A+ erythrocytes assessed as [3H]hypoxanthine incorporation by semi-automated micro dilution assay Plasmodium falciparum 0.0016 ug.mL-1
Antimalarial activity against chloroquine-resistant Plasmodium falciparum K1 Plasmodium falciparum K1 0.0013 ug.mL-1
Antimalarial activity against chloroquine-sensitive Plasmodium falciparum NF54 Plasmodium falciparum 0.0016 ug.mL-1
Antimicrobial activity against Plasmodium vivax trophozoites by microscopy Plasmodium vivax 1.61 nM
Antimicrobial activity against Plasmodium vivax at the ring stage by microscopy Plasmodium vivax 0.86 nM
Antimicrobial activity against Plasmodium vivax trophozoites measured after 30 hrs by microscopy Plasmodium vivax 1.2 nM
Antimicrobial activity against Plasmodium vivax at the ring stage measured after 30 hrs by microscopy Plasmodium vivax 0.83 nM
Antimicrobial activity against Plasmodium vivax trophozoites measured within 30 hrs by microscopy Plasmodium vivax 1.6 nM
Antimicrobial activity against Plasmodium vivax at the ring stage measured within 30 hrs by microscopy Plasmodium vivax 1.39 nM
Induction of heme alkylation of Fe(II) heme assessed as loss of heme at 10 uM in presence of 50% ACN-H2O with excess sodium dithionite under argon at 20 degC by spectrophotometry None 44.0 %
Antimalarial activity against chloroquine-resistant Plasmodium falciparum K1 Plasmodium falciparum K1 3.2 nM
Antimicrobial activity against Plasmodium vivax at trophozoite stage Plasmodium vivax 8.0 nM
Antimicrobial activity against Plasmodium falciparum at ring stage Plasmodium falciparum 8.0 nM
Antimalarial activity against chloroquine-resistant Plasmodium vivax by Giemsa staining Plasmodium vivax 1.29 nM
Antiparasitic activity against Toxoplasma gondii RH infected in human foreskin fibroblasts monolayer after 72 hrs by bacterial beta-galactosidase reporter gene assay Toxoplasma gondii RH 213.0 nM
Antiplasmodial activity against Plasmodium falciparum 3D7 infected in RBCs by firefly luciferase reporter gene assay Plasmodium falciparum 3.3 nM
Antimalarial activity against Plasmodium falciparum infected in human erythrocytes assessed as growth inhibition by microscopic analysis using giemsa staining Plasmodium falciparum 0.68 nM
Antimalarial activity against Plasmodium vivax infected in human erythrocytes assessed as growth inhibition by microscopic analysis using giemsa staining Plasmodium vivax 1.03 nM
Antimalarial activity against Plasmodium vivax with >50% parasites at ring stage infected in human erythrocytes assessed as growth inhibition after 30 to 50 hrs by microscopic analysis using giemsa staining Plasmodium vivax 1.27 nM
Antimalarial activity against Plasmodium falciparum 7G8 harboring pfATP6 L263 mutant assessed as inhibition of [3H]hypoxanthine incorporation Plasmodium falciparum 7G8 13.5 nM
Antimalarial activity against Plasmodium falciparum 7G8 harboring pfATP6 263E mutant assessed as inhibition of [3H]hypoxanthine incorporation Plasmodium falciparum 7G8 14.9 nM
Antimalarial activity against Plasmodium falciparum D10 harboring pfATP6 L263 mutant assessed as inhibition of [3H]hypoxanthine incorporation Plasmodium falciparum D10 23.6 nM
Antimalarial activity against Plasmodium falciparum D10 harboring pfATP6 263E mutant assessed as inhibition of [3H]hypoxanthine incorporation Plasmodium falciparum D10 26.2 nM
Antimalarial activity against Plasmodium falciparum 7G8 clone 1 harboring pfATP6 L263 mutant assessed as inhibition of [3H]hypoxanthine incorporation Plasmodium falciparum 7G8 13.5 nM
Antimalarial activity against Plasmodium falciparum 7G8 clone 1 assessed as inhibition of [3H]hypoxanthine incorporation Plasmodium falciparum 7G8 14.2 nM
Antimalarial activity against Plasmodium falciparum 7G8 clone 2 assessed as inhibition of [3H]hypoxanthine incorporation Plasmodium falciparum 7G8 12.1 nM
Antimalarial activity against Plasmodium falciparum 7G8 clone M1 harboring pfATP6 L263 mutant assessed as inhibition of [3H]hypoxanthine incorporation Plasmodium falciparum 7G8 14.9 nM
Antimalarial activity against Plasmodium falciparum 7G8 clone M1 assessed as inhibition of [3H]hypoxanthine incorporation Plasmodium falciparum 7G8 16.0 nM
Antimalarial activity against Plasmodium falciparum 7G8 clone M2 assessed as inhibition of [3H]hypoxanthine incorporation Plasmodium falciparum 7G8 13.3 nM
Antimalarial activity against Plasmodium falciparum 7G8 clone M3 assessed as inhibition of [3H]hypoxanthine incorporation Plasmodium falciparum 7G8 12.4 nM
Antimalarial activity against Plasmodium falciparum 7G8 clone M4 assessed as inhibition of [3H]hypoxanthine incorporation Plasmodium falciparum 7G8 21.3 nM
Antimalarial activity against Plasmodium falciparum D10 clone 1 harboring pfATP6 L263 mutant assessed as inhibition of [3H]hypoxanthine incorporation Plasmodium falciparum D10 23.6 nM
Antimalarial activity against Plasmodium falciparum D10 clone 1 assessed as inhibition of [3H]hypoxanthine incorporation Plasmodium falciparum D10 26.6 nM
Antimalarial activity against Plasmodium falciparum D10 clone 2 assessed as inhibition of [3H]hypoxanthine incorporation Plasmodium falciparum D10 16.8 nM
Antimalarial activity against Plasmodium falciparum D10 clone M1 harboring pfATP6 L263 mutant assessed as inhibition of [3H]hypoxanthine incorporation Plasmodium falciparum D10 26.2 nM
Antimalarial activity against Plasmodium falciparum D10 clone M1 assessed as inhibition of [3H]hypoxanthine incorporation Plasmodium falciparum D10 26.5 nM
Antimalarial activity against Plasmodium falciparum D10 clone M2 assessed as inhibition of [3H]hypoxanthine incorporation Plasmodium falciparum D10 27.7 nM
Antimalarial activity against Plasmodium falciparum D10 clone M3 assessed as inhibition of [3H]hypoxanthine incorporation Plasmodium falciparum D10 24.3 nM
Antimalarial activity against Plasmodium malariae trophozoite stage infected in red blood cells in presence of AB+ human serum by drug susceptibility assay Plasmodium malariae 2.84 nM
Antimalarial activity against Plasmodium malariae ring stage infected in red blood cells in presence of AB+ human serum by drug susceptibility assay Plasmodium malariae 1.77 nM
Antimalarial activity against Plasmodium ovale trophozoite stage infected in red blood cells in presence of AB+ human serum by drug susceptibility assay Plasmodium ovale 1.28 nM
Antimalarial activity against Plasmodium ovale ring stage infected in red blood cells in presence of AB+ human serum by drug susceptibility assay Plasmodium ovale 1.16 nM
Antimalarial activity against trophozoites stage of Plasmodium vivax assessed as parasites growth inhibition using giemsa staining after 24 to 56 hrs by microscopic analysis in presence of 20% human serum Plasmodium vivax 0.39 nM
Antimalarial activity against ring stage of Plasmodium vivax assessed as parasites growth inhibition using giemsa staining after 24 to 56 hrs by microscopic analysis in presence of 20% human serum Plasmodium vivax 0.75 nM
Antimalarial activity against trophozoites stage of Plasmodium falciparum assessed as parasites growth inhibition using giemsa staining after 24 to 56 hrs by microscopic analysis in presence of 10% human serum Plasmodium falciparum 1.19 nM
Antimalarial activity against ring stage of Plasmodium falciparum assessed as parasites growth inhibition using giemsa staining after 24 to 56 hrs by microscopic analysis in presence of 10% human serum Plasmodium falciparum 0.88 nM
Antimalarial activity against Plasmodium vivax assessed as parasites growth inhibition using giemsa staining after 24 to 56 hrs by microscopic analysis in presence of 20% human serum Plasmodium vivax 0.74 nM
Antimalarial activity against Plasmodium falciparum assessed as parasites growth inhibition using giemsa staining after 24 to 56 hrs by microscopic analysis in presence of 10% human serum Plasmodium falciparum 0.92 nM
Antimalarial activity against chloroquine-sensitive Plasmodium falciparum 3D7 assessed as inhibition of [3H]hypoxanthine incorporation Plasmodium falciparum 2.0 nM
Antimalarial activity against chloroquine-resistant Plasmodium falciparum K1 assessed as inhibition of [3H]hypoxanthine incorporation Plasmodium falciparum K1 1.0 nM
Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum NF54 Plasmodium falciparum 4.0 nM
Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum K1 Plasmodium falciparum K1 3.0 nM
Antiplasmodial activity chloroquine-sensitive Plasmodium falciparum 3D7 infected in human A+ erythrocytes assessed as inhibition of [3H]-hypoxanthine incorporation after 24 hrs by scintillation counting Plasmodium falciparum 5.3 nM
Antiplasmodial activity chloroquine-resistant Plasmodium falciparum K1 infected in human A+ erythrocytes assessed as inhibition of [3H]-hypoxanthine incorporation after 24 hrs by scintillation counting Plasmodium falciparum K1 2.8 nM
OSM: Inhibition of Plasmodium falciparum 3D7 growth using a SYBR green I fluorescence based assay. GSK Tres Cantos. Plasmodium falciparum 3D7 19.0 nM
Inhibition of electric eel AChE at 2 mg/ml by Ellman's method Electrophorus electricus -5.55 %
Inhibition of horse BChE at 2 mg/ml by Ellman's method Equus caballus 4.77 %
Antimicrobial activity against Plasmodium falciparum NF54 Plasmodium falciparum 2.5 nM
Antiplasmodial activity against Plasmodium falciparum assessed as inhibition of [3H]hypoxanthine incorporation Plasmodium falciparum 17.0 nM
Antimalarial activity against chloroquine-sensitive Plasmodium falciparum NF54 infected in mouse at 30 mg/kg, po Plasmodium falciparum 4.2 nM
Antimalarial activity against chloroquine-resistant Plasmodium falciparum K1 Plasmodium falciparum K1 3.4 nM
Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum K1 infected in human erythrocytes after 48 hrs by [3H]-hypoxanthine incorporation assay Plasmodium falciparum K1 3.1 nM
Antimalarial activity against chloroquine-resistant Plasmodium falciparum 3D7 Plasmodium falciparum 0.002 ug.mL-1
Antimalarial activity against chloroquine-resistant Plasmodium falciparum Dd2 Plasmodium falciparum 31.2 nM
Gametocytocidal activity against synchronous stage 4 to 5 of transgenic Plasmodium falciparum NF54 gametocyte harboring pfs16 promoter assessed as parasite viability after 72 hrs by MitoTracker Red CMXRos-based assay Plasmodium falciparum 8.0 nM
Gametocytocidal activity against synchronous stage 1 to 3 of transgenic Plasmodium falciparum NF54 gametocyte harboring pfs16 promoter assessed as parasite viability after 72 hrs by luciferase reporter gene assay Plasmodium falciparum 19.0 nM
Antimalarial activity against mature gametocytic stage of Plasmodium falciparum assessed as inhibition of mature gamete exflagellation at 10 uM incubated for 24 hrs prior to exflagellation induction at 21 degC measured after 20 mins by microscopic analysis relative to control Plasmodium falciparum 50.0 %
Antimalarial activity against asexual stage of Plasmodium falciparum 3D7 after 72 hrs by image-based HTS assay Plasmodium falciparum 2.2 nM
Antimalarial activity against late (4 to 5) gametocytic stage of Plasmodium falciparum after 72 hrs by image-based HTS assay Plasmodium falciparum 3.43 nM
Antimalarial activity against Plasmodium berghei ANKA infected in mouse assessed as inhibition of parasitemia at 30 mg/kg, po administered for 3 days post-infection measured on day 4 by Giemsa staining relative to control Plasmodium berghei 99.7 %
Antimalarial activity against Plasmodium berghei ANKA infected in mouse assessed as inhibition of parasitemia at 10 mg/kg, po administered for 3 days post-infection measured on day 4 by Giemsa staining relative to control Plasmodium berghei 95.2 %
Antimalarial activity against Plasmodium berghei ANKA infected in mouse assessed as inhibition of parasitemia at 3 mg/kg, po administered for 3 days post-infection measured on day 4 by Giemsa staining relative to control Plasmodium berghei 62.4 %
Antimalarial activity against Plasmodium berghei ANKA infected in mouse assessed as inhibition of parasitemia at 1 mg/kg, po administered for 3 days post-infection measured on day 4 by Giemsa staining relative to control Plasmodium berghei 38.5 %
Antimalarial activity against chloroquine-sensitive Plasmodium falciparum 3D7 assessed as parasite growth inhibition after 48 hrs by SYBR green-1 dye-based fluorescence assay Plasmodium falciparum 3D7 1.6 nM
Antiplasmodial activity chloroquine-resistant Plasmodium falciparum Dd2 by lactate dehydrogenase assay Plasmodium falciparum Dd2 46.0 nM
Antiplasmodial activity chloroquine-sensitive Plasmodium falciparum NF54 by lactate dehydrogenase assay Plasmodium falciparum NF54 5.0 nM
Antiplasmodial activity against chloroquine-resistant asexual erythrocytic stage of Plasmodium falciparum Dd2 assessed as parasite growth inhibition by lactate dehydrogenase assay Plasmodium falciparum Dd2 31.2 nM
Antiplasmodial activity against chloroquine-sensitive asexual erythrocytic stage of Plasmodium falciparum D10 assessed as parasite growth inhibition by lactate dehydrogenase assay Plasmodium falciparum D10 6.3 nM
Antiplasmodial activity against asexual erythrocytic stage of chloroquine-resistant Plasmodium falciparum Dd2 assessed as parasite growth inhibition after 48 hrs by lactate dehydrogenase assay Plasmodium falciparum Dd2 8.1 nM
Antiplasmodial activity against asexual erythrocytic stage of chloroquine-sensitive Plasmodium falciparum NF54 assessed as parasite growth inhibition after 48 hrs by lactate dehydrogenase assay Plasmodium falciparum NF54 5.2 nM
Antimalarial activity against Plasmodium falciparum 3D7 assessed as growth inhibition after 3 days by HRP2 based ELISA Plasmodium falciparum 3D7 0.82 nM
Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum NF54 assessed as reduction in parasite growth by parasite lactate dehydrogenase assay Plasmodium falciparum NF54 0.0028 ug.mL-1
Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum K1 infected in human erythrocytes assessed as [3H]hypoxanthine incorporation after 48 hrs by betaplate liquid scintillation counting analysis Plasmodium falciparum K1 4.9 nM
Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum NF54 by LDH assay Plasmodium falciparum NF54 20.0 nM
Antimalarial activity against multidrug-resistant Plasmodium falciparum K1 Plasmodium falciparum K1 3.0 nM
Antimalarial activity against drug-sensitive Plasmodium falciparum NF54 Plasmodium falciparum NF54 4.0 nM
Antimalarial activity against late stage gametocyte stage of Plasmodium falciparum NF54 after 72 hrs Plasmodium falciparum NF54 3.8 nM
Antiplasmodial activity against Plasmodium falciparum 3D7 asexual blood stages after 3 days by HRP2 detection based ELISA method Plasmodium falciparum 3D7 1.9 nM
Antiplasmodial activity against Plasmodium falciparum Dd2 asexual blood stages after 3 days by HRP2 detection based ELISA method Plasmodium falciparum Dd2 2.0 nM
Gametocytocidal activity against transgenic Plasmodium falciparum NF54-pfs16-GFP late stage gametocytes after 72 hrs by mitotracker red CM-H2XRos dye based confocal imaging assay Plasmodium falciparum NF54 44.0 nM
Antimalarial activity against Plasmodium berghei ANKA infected in CD1 Swiss albino mouse assessed as reduction in parasitemia Plasmodium berghei ANKA 97.0 %
Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum NF54 asexual erythrocyte stages by parasite lactate dehydrogenase assay Plasmodium falciparum NF54 5.2 nM
Antigametocytocidal activity against Plasmodium falciparum NF54-pfs16-GPF early (1 to 3) gametocyte assessed as viability after 72 hrs by MitoTracker Red CM-H2XRos/micro-plate confocal imaging system Plasmodium falciparum NF54 3.0 nM
Antigametocytocidal activity against Plasmodium falciparum NF54-pfs16-GPF late (4 to 6) gametocyte assessed as viability after 72 hrs by MitoTracker Red CM-H2XRos/micro-plate confocal imaging system Plasmodium falciparum NF54 12.0 nM
Antimalarial activity against Plasmodium berghei ANKA expressing GFP infected in Balb/c mouse assessed as inhibition of parasitemia at 50 mg/kg administered as single dose on day 1 of infection measured on day 3 post exposure relative to control Plasmodium berghei ANKA 97.0 %
Antimalarial activity against Plasmodium berghei ANKA expressing GFP infected in Balb/c mouse assessed as inhibition of parasitemia at 50 mg/kg administered as single dose on day 1 of infection measured on day 6 post exposure relative to control Plasmodium berghei ANKA 81.0 %
Antimalarial activity against chloroquine-sensitive Plasmodium falciparum 3D7 assessed as inhibition of parasite proliferation after 96 hrs by SYBR Green I-based fluorescence method Plasmodium falciparum 3D7 4.0 nM
Antimalarial activity against chloroquine-resistant Plasmodium falciparum W2 assessed as inhibition of parasite proliferation after 96 hrs by SYBR Green I-based fluorescence method Plasmodium falciparum 5.71 nM
Antiplasmodial activity against chloroquine-sensitive asexual erythrocytic stage of Plasmodium falciparum NF54 assessed as [3H]-hypoxanthine incorporation by lactate dehydrogenase assay Plasmodium falciparum NF54 5.0 nM
Antiplasmodial activity against chloroquine-resistant asexual erythrocytic stage of Plasmodium falciparum Dd2 assessed as [3H]-hypoxanthine incorporation by lactate dehydrogenase assay Plasmodium falciparum Dd2 11.0 nM
Antiplasmodial activity against multi-drug resistant Plasmodium falciparum K1 infected in human erythrocytes assessed as parasite growth inhibition after 72 hrs by SYBR Green I dye-based fluorescence assay in presence of ascorbic acid Plasmodium falciparum K1 700.0 nM
Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum K1 Plasmodium falciparum K1 3.5 nM
Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum 3D7 Plasmodium falciparum 3D7 4.2 nM
Antiplasmodial activity against chloroquine/mefloquine-resistant Plasmodium falciparum SKF58 Plasmodium falciparum 10.0 nM
Antiplasmodial activity against chloroquine/mefloquine-resistant Plasmodium falciparum SRIV35 Plasmodium falciparum 4.1 nM
Antimalarial activity against CQ-resistant Plasmodium falciparum W2 cultivated in human type O+ red blood cells assessed as reduction in parasite infection incubated for 48 hrs by microscopy Plasmodium falciparum 0.39 ug.mL-1
Antitumor activity against human MCF7 cells xenografted in BALB/c nude mouse assessed as decrease in tumor volume at 0.023 mmol/kg, ip administered every 2 days for 3 times measured after day 6 Homo sapiens 40.21 %
Antimalarial activity against chloroquine-resistant Plasmodium falciparum K1 Plasmodium falciparum K1 10.0 nM
Antimalarial activity against Plasmodium falciparum FCR-3/Gambia Plasmodium falciparum FCR-3/Gambia 2.5 nM
Antiplasmodial activity against chloroquine-resistant asexual erythrocytic stage of Plasmodium falciparum Dd2 assessed as parasite growth inhibition by parasite lactate dehydrogenase assay Plasmodium falciparum Dd2 5.2 nM
Antiplasmodial activity against chloroquine-sensitive asexual erythrocytic stage of Plasmodium falciparum NF54 assessed as parasite growth inhibition by parasite lactate dehydrogenase assay Plasmodium falciparum NF54 24.2 nM
Antimalarial activity against Plasmodium falciparum 3D7 infected in human erythrocytes assessed as parasite growth inhibition after 72 hrs by SYBR Green I assay Plasmodium falciparum 3D7 9.0 nM
Cytotoxicity against human CCRF-CEM cells assessed as cell viability after 72 hrs by resazurin assay Homo sapiens 70.0 nM
Cytotoxicity against human CEM/ADR5000 cells assessed as cell viability after 72 hrs by resazurin assay Homo sapiens 190.0 nM
Antiplasmodial activity against blood stage of chloroquine-sensitive Plasmodium falciparum NF54 by parasite lactate dehydrogenase assay Plasmodium falciparum NF54 4.4 nM
Antiplasmodial activity against multidrug-resistant Plasmodium falciparum K1 by [3H]-hypoxanthine incorporation assay Plasmodium falciparum K1 3.0 nM
Antiplasmodial activity against multidrug-sensitive Plasmodium falciparum NF54 by [3H]-hypoxanthine incorporation assay Plasmodium falciparum NF54 4.0 nM
Antimalarial activity against chloroquine-resistant Plasmodium falciparum Dd2 infected in human erythrocyte assessed as growth inhibition by SYBR Green-1 assay Plasmodium falciparum Dd2 1.76 nM
Antimalarial activity against chloroquine-sensitive Plasmodium falciparum 3D7 infected in human erythrocyte assessed as growth inhibition by SYBR Green-1 assay Plasmodium falciparum 3D7 1.97 nM
Antiplasmodial activity against multidrug resistant Plasmodium falciparum K1 infected in human erythrocytes after 48 hrs by [3H]-hypoxanthine incorporation assay Plasmodium falciparum K1 4.0 nM
Antiplasmodial activity against drug sensitive Plasmodium falciparum NF54 infected in human erythrocytes after 48 hrs by [3H]-hypoxanthine incorporation assay Plasmodium falciparum NF54 3.0 nM
Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum 3D7 assessed as inhibition of parasite growth after 72 hrs by DAPI staining-based confocal microscopic analysis Plasmodium falciparum 3D7 0.5 nM
Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum Dd2 assessed as inhibition of parasite growth after 72 hrs by DAPI staining-based confocal microscopic analysis Plasmodium falciparum Dd2 0.443 nM
Antiparasitic activity against Plasmodium falciparum Dd2 assessed as growth inhibition after 72 hrs by DAPI staining-based confocal image analysis Plasmodium falciparum Dd2 1.3 nM
Antiparasitic activity against Plasmodium falciparum 3D7 assessed as growth inhibition after 72 hrs by DAPI staining-based confocal image analysis Plasmodium falciparum 3D7 2.1 nM
Antiparasitic activity against chloroquine/quinine/pyrimethamine/sulfadoxine/NITD609-resistant Plasmodium falciparum Dd2 clone 2 assessed as growth inhibition after 72 hrs by DAPI staining-based confocal image analysis Plasmodium falciparum Dd2 0.9 nM
Antiplasmodial activity against chloroquine sensitive Plasmodium falciparum NF54 infected in human RBC after 48 hrs by [3H]hypoxanthine incorporation assay Plasmodium falciparum NF54 4.0 nM
Antimalarial activity against chloroquine-sensitive asexual Plasmodium falciparum NF54 infected in human erythrocytes assessed as inhibition of parasite proliferation after 96 hrs by SYBR Green I fluorescence based assay Plasmodium falciparum NF54 7.88 nM
Antimalarial activity against multidrug resistant Plasmodium falciparum K1 infected in human erythrocytes assessed as inhibition of parasite proliferation after 96 hrs by SYBR Green I fluorescence based assay Plasmodium falciparum K1 8.97 nM
Antimalarial activity against multidrug resistant Plasmodium falciparum W2 infected in human erythrocytes assessed as inhibition of parasite proliferation after 96 hrs by SYBR Green I fluorescence based assay Plasmodium falciparum 6.77 nM
Antiplasmodial activity against erythrocytic stage of chloroquine/pyrimethamine/cycloguanil resistant-Plasmodium falciparum FCR3 after 48 hrs by [3H]-hypoxanthine incorporation assay Plasmodium falciparum FCR-3/Gambia 0.00091 ug.mL-1
Antiplasmodial activity against chloroquine-sensitive asexual erythrocyte stage form Plasmodium falciparum NF54 measured after 48 hrs by pLDH assay Plasmodium falciparum NF54 8.0 nM
Antiplasmodial activity against chloroquine-resistant asexual erythrocyte stage form Plasmodium falciparum Dd2 measured after 48 hrs by pLDH assay Plasmodium falciparum Dd2 7.5 nM
Antimalarial activity against Plasmodium falciparum 3D7 asexual blood stage infected in human erythrocytes incubated for 72 hrs by LDH assay Plasmodium falciparum 3D7 8.0 nM
Antimalarial activity against chloroquine and mefloquine resistant Plasmodium falciparum W2mef infected in human erythrocytes incubated for 72 hrs by LDH assay Plasmodium falciparum 6.0 nM
Antimalarial activity against Plasmodium falciparum NF54 harboring pfs16-LUC-GFP ring stage gametocytes after 24 hrs by MitoTracker Red staining based confocal microscopy Plasmodium falciparum NF54 3.0 nM
Antimalarial activity against Plasmodium falciparum NF54 harboring pfs16-LUC-GFP early stage 1 to 3 gametocytes after 48 hrs by MitoTracker Red staining based confocal microscopy Plasmodium falciparum NF54 3.0 nM
Antimalarial activity against Plasmodium falciparum NF54 harboring pfs16-LUC-GFP late stage 4 to 5 gametocytes after 48 hrs by MitoTracker Red staining based confocal microscopy Plasmodium falciparum NF54 8.0 nM
Antimalarial activity against chloroquine-sensitive asexual intraerythrocytic stage of Plasmodium falciparum NF54 assessed as inhibition of parasite growth by lactate dehydrogenase assay Plasmodium falciparum NF54 12.6 nM
Antimalarial activity against chloroquine-resistant asexual intraerythrocytic stage of Plasmodium falciparum Dd2 assessed as inhibition of parasite growth by lactate dehydrogenase assay Plasmodium falciparum Dd2 17.4 nM
Antimalarial activity against chloroquine-sensitive Plasmodium falciparum 3D7 infected in human RBC after 72 hrs by DAPI staining based confocal microscopic method Plasmodium falciparum 3D7 0.48 nM
Antimalarial activity against chloroquine-resistant Plasmodium falciparum Dd2 infected in human RBC after 72 hrs by DAPI staining based confocal microscopic method Plasmodium falciparum Dd2 0.44 nM
Antispasmodial activity against chloroquine-sensitive asexual blood stages of Plasmodium falciparum 3D7 after 72 hrs by HRP2-based ELISA Plasmodium falciparum 3D7 1.9 nM
Antispasmodial activity against multidrug-resistant asexual blood stages of Plasmodium falciparum Dd2 after 72 hrs by HRP2-based ELISA Plasmodium falciparum Dd2 2.0 nM
Gametocytocidal activity against transgenic GFP-fused Plasmodium falciparum NF54 ring stage gametocytes after 72 hrs by Mitotracker Red CMH2XRos staining based confocal microscopic method Plasmodium falciparum NF54 3.0 nM
Gametocytocidal activity against transgenic GFP-fused Plasmodium falciparum NF54 early stage gametocytes after 72 hrs by Mitotracker Red CMH2XRos staining based confocal microscopic method Plasmodium falciparum NF54 3.0 nM
Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum 3D7 measured after 72 hrs by DAPI staining based high throughput screening assay Plasmodium falciparum 3D7 1.0 nM
Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum Dd2 measured after 72 hrs by DAPI staining based high throughput screening assay Plasmodium falciparum Dd2 0.67 nM
Antiplasmodial activity against chloroquine-sensitive synchronized trophozoite stage of Plasmodium falciparum NF54 after 48 hrs by NBT dye based LDH assay Plasmodium falciparum NF54 5.6 nM
Antiplasmodial activity against chloroquine-resistant synchronized trophozoite stage of Plasmodium falciparum Dd2 after 48 hrs by NBT dye based LDH assay Plasmodium falciparum Dd2 14.3 nM
Antiplasmodial activity against chloroquine-resistant synchronized trophozoite stage of Plasmodium falciparum 7G8 after 48 hrs by NBT dye based LDH assay Plasmodium falciparum 7G8 7.7 nM
Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum NF54 by LDH assay Plasmodium falciparum NF54 9.3 nM
Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum K1 by [3H]hypoxanthine incorporation assay Plasmodium falciparum K1 2.6 nM
Antimalarial activity against Plasmodium falciparum 3D7 after 72 hrs by DAPI staining-based fluorescence microscopic analysis Plasmodium falciparum 3D7 0.9 nM
Antimalarial activity against Plasmodium falciparum Dd2 after 72 hrs by DAPI staining-based fluorescence microscopic analysis Plasmodium falciparum Dd2 1.0 nM
Cytotoxicity against human CCRF-CEM cells assessed as reduction in cell viability after 72 hrs by resazurin dye based assay Homo sapiens 69.0 nM
Cytotoxicity against human CEM/ADR5000 cells over-expressing P-gp assessed as reduction in cell viability after 72 hrs by resazurin dye based assay Homo sapiens 189.0 nM
Antimalarial activity against Plasmodium falciparum 3D7 infected in human erythrocytes after 72 hrs by SYBR green dye fluorescence assay Plasmodium falciparum 3D7 9.7 nM
Antimalarial activity against chloroquine-resistant Plasmodium falciparum Dd2 after 72 hrs by DAPI staining based confocal microplate imaging method Plasmodium falciparum Dd2 1.0 nM
Antimalarial activity against chloroquine-sensitive Plasmodium falciparum 3D7 after 72 hrs by DAPI staining based confocal microplate imaging method Plasmodium falciparum 3D7 1.0 nM
Antiplasmodial activity against drug-sensitive blood stage Plasmodium falciparum 3D7 by SYBR green 1 staining based fluorescence assay Plasmodium falciparum 3D7 4.0 nM
Antiplasmodial activity against chloroquine/cycloguanil/pyrimethamine-resistant blood stage Plasmodium falciparum K1 by SYBR green 1 staining based fluorescence assay Plasmodium falciparum K1 3.0 nM
Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum Dd2 by LDH release assay Plasmodium falciparum Dd2 15.0 nM
Cytotoxicity against human CCRF-CEM cells assessed as reduction in cell viability after 72 hrs by resazurin dye based assay Homo sapiens 400.0 nM
Cytotoxicity against human CEM/ADR5000 cells overexpressing P-gp assessed as reduction in cell viability after 72 hrs by resazurin dye based assay Homo sapiens 100.0 nM
Antiplasmodial activity against Plasmodium falciparum 3D7 ring stage parasites infected in human erythrocytes after 72 hrs by SYBR Green 1 dye based fluorescence assay Plasmodium falciparum 3D7 8.2 nM
Antiplasmodial activity against drug-sensitive Plasmodium falciparum 3D7 ring stage infected in human erythrocytes after 72 hrs by DAPI staining based method Plasmodium falciparum 3D7 1.0 nM
Antiplasmodial activity against 4-aminoquinoline/antifolates-resistant Plasmodium falciparum Dd2 ring stage infected in human erythrocytes after 72 hrs by DAPI staining based method Plasmodium falciparum Dd2 0.67 nM
Antimalarial activity against drug-sensitive Plasmodium falciparum NF54 Plasmodium falciparum NF54 4.0 nM
Antimalarial activity against multidrug-resistant Plasmodium falciparum K1 Plasmodium falciparum K1 3.0 nM
Antiplasmodial activity against chloroquine and pyrimethamine resistant Plasmodium falciparum K1 assessed as reduction in [3H]-hypoxanthine incorporation incubated for 48 hrs by liquid scintillation counting method Plasmodium falciparum K1 0.5 nM
Antiplasmodial activity against chloroquine sensitive Plasmodium falciparum NF54 assessed as reduction in [3H]-hypoxanthine incorporation incubated for 48 hrs by liquid scintillation counting method Plasmodium falciparum NF54 2.6 nM
Antimalarial activity against chloroquine-sensitive Plasmodium falciparum 3D7 after 72 hrs by DAPI staining based fluorescence assay Plasmodium falciparum 3D7 0.9 nM
Antimalarial activity against chloroquine-resistant Plasmodium falciparum Dd2 after 72 hrs by DAPI staining based fluorescence assay Plasmodium falciparum Dd2 1.0 nM
Antimalarial activity against Plasmodium falciparum NF54 infected in human erythrocytes assessed as reduction in [3H]hypoxanthine incorporation preincubated for 48 hrs followed by [3H]hypoxanthine addition measured after 24 hrs by liquid scintillation counting Plasmodium falciparum NF54 4.0 nM
Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum NF54 Plasmodium falciparum NF54 9.41 nM
Gametocytocidal activity against transgenic GFP-fused Plasmodium falciparum NF54 early stage gametocytes after 72 hrs by Mitotracker Red CMH2XRos staining based imaging method Plasmodium falciparum NF54 3.0 nM
Gametocytocidal activity against transgenic GFP-fused Plasmodium falciparum NF54 late stage gametocytes after 72 hrs by Mitotracker Red CMH2XRos staining based imaging method Plasmodium falciparum NF54 8.0 nM
Antimalarial activity against Plasmodium berghei N infected in mouse assessed as inhibition of parasitemia at 15 mg/kg, po once daily for 4 consecutive days starting from 2 hrs post infection measured on day 4 post last dose relative to control Plasmodium berghei 95.2 %
Antimalarial activity against synchronized ring stage of Plasmodium falciparum 3D7 infected in human erythrocytes after 72 hrs by SYBR Green1 dye based fluorescence assay Plasmodium falciparum 3D7 8.9 nM
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells at 10 uM after 48 hours by high content imaging Homo sapiens 2.39 %
Antimalarial activity against Plasmodium falciparum K1 infected in human erythrocytes preincubated for 48 hrs followed by [3H]-hypoxanthine addition and measured after 24 hrs by liquid scintillation counting Plasmodium falciparum 3.0 nM
Antimalarial activity against Plasmodium falciparum NF54 infected in human erythrocytes preincubated for 48 hrs followed by [3H]-hypoxanthine addition and measured after 24 hrs by liquid scintillation counting Plasmodium falciparum 194.0 nM
Antiplasmodial activity against Plasmodium falciparum NF54 after 48 hrs by lactate dehydrogenase assay Plasmodium falciparum 194.0 nM
Antiplasmodial activity against Plasmodium falciparum K1 after 48 hrs by lactate dehydrogenase assay Plasmodium falciparum 3.0 nM
Antimalarial activity against synchronized ring stage Plasmodium falciparum 3D7 transfected with nano-luciferase assessed as parasite growth inhibition after 48 hrs by Nano-Glo luciferase assay Plasmodium falciparum 1.64 nM
Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum NF54 infected in human erythrocytes assessed as reduction in [3H]hypoxanthine incorporation preincubated for 48 hrs followed by [3H]hypoxanthine addition measured after 24 hrs by liquid scintillation counting method Plasmodium falciparum 0.0022 ug.mL-1
Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum K1 infected in human erythrocytes assessed as reduction in [3H]hypoxanthine incorporation preincubated for 48 hrs followed by [3H]hypoxanthine addition measured after 24 hrs by liquid scintillation counting method Plasmodium falciparum 0.00093 ug.mL-1
Antimalarial activity against asexual stage of Plasmodium falciparum Dd2 infected in erythrocytes assessed as reduction in parasite growth incubated for 48 hrs under hypoxic condition by Hoechst 33342 staining based flow cytometry Plasmodium falciparum 13.3 nM
Antimalarial activity against asexual stage of Plasmodium falciparum 3D7 infected in erythrocytes assessed as reduction in parasite growth incubated for 48 hrs under hypoxic condition by Hoechst 33342 staining based flow cytometry Plasmodium falciparum 22.8 nM
Antimalarial activity against asexual stage of Plasmodium falciparum NF54 assessed as reduction in parasite growth incubated for 96 hrs by SYBR Green I dye-based fluorescence assay Plasmodium falciparum 3.0 nM
Antimalarial activity against asexual stage of Plasmodium falciparum K1 assessed as reduction in parasite growth incubated for 96 hrs by SYBR Green I dye-based fluorescence assay Plasmodium falciparum 3.26 nM
Antimalarial activity against asexual stage of Plasmodium falciparum W2 assessed as reduction in parasite growth incubated for 96 hrs by SYBR Green I dye-based fluorescence assay Plasmodium falciparum 2.4 nM
Antimalarial activity against Plasmodium falciparum NF54 early gametocytes transfected with luciferase gene incubated for 48 hrs by luciferase reporter gene assay Plasmodium falciparum 63.0 nM
Antimalarial activity against Plasmodium falciparum NF54 late gametocytes transfected with luciferase gene incubated for 48 hrs by luciferase reporter gene assay Plasmodium falciparum 259.0 nM
Antimalarial activity against Plasmodium falciparum NF54 incubated for 48 hrs by [3H]-hypoxanthine incorporation assay Plasmodium falciparum 3.2 nM
Antimalarial activity against Plasmodium falciparum K1 incubated for 48 hrs by [3H]-hypoxanthine incorporation assay Plasmodium falciparum 1.4 nM
Antimalarial activity against Plasmodium falciparum TM90C2B incubated for 48 hrs by [3H]-hypoxanthine incorporation assay Plasmodium falciparum 2.7 nM
Antimalarial activity against Plasmodium falciparum 3D7 infected in human erythrocytes after 72 hrs by SYBR Green1 dye based fluorescence assay relative to control Plasmodium falciparum 9.7 nM
Antimalarial activity against chloroquine-sensitive Plasmodium falciparum Nigerian infected in human blood after 48 hrs by [3H]-hypoxanthine incorporation assay Plasmodium falciparum 3.8 nM
Antiplasmodial activity against chloroquine-sensitive asexual blood stage of Plasmodium falciparum NF54 by LDH assay Plasmodium falciparum 9.8 nM
Antiplasmodium activity against chloroquine-sensitive Plasmodium falciparum NF54 asexual blood stage forms infected in human erythrocytes assessed as reduction in [3H]-hypoxanthine incorporation incubated for 48 hrs by liquid scintillation counting method Plasmodium falciparum 7.0 nM
Antiplasmodium activity against multidrug resistant Plasmodium falciparum K1 asexual blood stage forms infected in human erythrocytes assessed as reduction in [3H]-hypoxanthine incorporation incubated for 48 hrs by liquid scintillation counting method Plasmodium falciparum 2.9 nM
Antimalarial activity against ring stage Plasmodium falciparum 3D7 infected in type A-positive human erythrocytes after 72 hrs by SYBR green 1 dye-based fluorescence assay Plasmodium falciparum 9.7 nM
Antimalarial activity against Plasmodium falciparum 3D7 after 72 hrs by DAPI staining-based confocal imaging analysis Plasmodium falciparum 1.6 nM
Antimalarial activity against Plasmodium falciparum Dd2 after 72 hrs by DAPI staining-based confocal imaging analysis Plasmodium falciparum 1.0 nM
Antiplasmodial activity against chloroquine-sensitive asexual blood stage of Plasmodium falciparum NF54 infected in human RBC assessed as reduction in [3H]hypoxanthine incorporation preincubated for 48 hrs followed by [3H]hypoxanthine addition measured after 24 hrs by liquid scintillation counting method Plasmodium falciparum 4.0 nM
Antiplasmodial activity against chloroquine-resistant asexual blood stage of Plasmodium falciparum K1 infected in human RBC assessed as reduction in [3H]hypoxanthine incorporation preincubated for 48 hrs followed by [3H]hypoxanthine addition measured after 24 hrs by liquid scintillation counting method Plasmodium falciparum 3.0 nM
Anti-plasmodial activity against chloroquine-sensitive Plasmodium falciparum 3D7 infected in erythrocytes after 72 hrs by SYBR green dye based fluorescence assay Plasmodium falciparum 5.0 nM
Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum K1 infected in human erythrocytes assessed as reduction in [3H]hypoxanthine incorporation pretreated for 24 hrs followed by [3H]hypoxanthine addition and measured after 24 hrs by liquid scintillation counting method Plasmodium falciparum 3.0 nM
Antiproliferative activity against human HCT116 cells assessed as inhibition of cell viability after 48 hrs by MTS assay Homo sapiens 890.0 nM
Antimalarial activity against ring-stage multidrug-resistant Plasmodium falciparum Dd2 preincubated for 6 hrs followed by compound wash and measured after 66 hrs by Giemsa-staining based light microscopic analysis Plasmodium falciparum 4.6 nM
Antimalarial activity against ring-stage chloroquine-susceptible Plasmodium falciparum 3D7 preincubated for 6 hrs followed by compound wash and measured after 66 hrs by Giemsa-staining based light microscopic analysis Plasmodium falciparum 5.1 nM
Antiplasmodial activity against Plasmodium falciparum 3D7A erythrocytic stage assessed as reduction in [3H]hypoxanthine incorporation preincubated for 24 hrs followed by [3H]hypoxanthine addition and measured after 24 hrs by microbeta scintillation counting method Plasmodium falciparum 30.0 nM
Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum NF54 incubated for 48 hrs by parasite lactate dehydrogenase assay Plasmodium falciparum 10.0 nM
Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum Dd2 incubated for 48 hrs by parasite lactate dehydrogenase assay Plasmodium falciparum 13.0 nM
Antimalarial activity against chloroquine-sensitive Plasmodium falciparum FC27 infected in human RBC assessed as reduction in parasite growth after 35 to 56 hrs by nucleic acid staining based flow cytometry Plasmodium falciparum 2.9 nM
Antimalarial activity against chloroquine-resistant Plasmodium falciparum K1 infected in human RBC assessed as reduction in parasite growth after 35 to 56 hrs by nucleic acid staining based flow cytometry Plasmodium falciparum 2.3 nM
Antimalarial activity against multidrug-resistant Plasmodium falciparum clinical isolates infected assessed as reduction in parasite growth after 35 to 56 hrs by nucleic acid staining based flow cytometry Plasmodium falciparum 2.1 nM
Antimalarial activity against multidrug-resistant Plasmodium vivax clinical isolates assessed as reduction in parasite growth after 35 to 56 hrs by nucleic acid staining based flow cytometry Plasmodium vivax 3.3 nM
Antiplasmodial activity against drug-sensitive Plasmodium falciparum 3D7 ring stage forms assessed as inhibition of parasite growth after 72 hrs by DAPI staining-based confocal microscopic analysis Plasmodium falciparum 2.1 nM
Antiplasmodial activity against drug-resistant Plasmodium falciparum Dd2 ring stage forms assessed as inhibition of parasite growth after 72 hrs by DAPI staining-based confocal microscopic analysis Plasmodium falciparum 3.3 nM
SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate Severe acute respiratory syndrome coronavirus 2 27.12 % SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate Severe acute respiratory syndrome coronavirus 2 4.084 %
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus -0.02 % Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus 2.55 % Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus 2.55 % Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus -0.02 %
Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum 3D7 incubated for 72 hrs by DAPI-staining based imaging analysis Plasmodium falciparum 0.3 nM
Antimalarial activity against chloroquine-sensitive Plasmodium falciparum 3D7 assessed as reduction in parasite rowth incubated for 72 hrs by DAPI staining based fluorescence assay Plasmodium falciparum 0.48 nM
Antimalarial activity against chloroquine-resistant Plasmodium falciparum Dd2 assessed as reduction in parasite growth incubated for 72 hrs by DAPI staining based fluorescence assay Plasmodium falciparum 0.44 nM
Antimalarial activity against chloroquine-sensitive Plasmodium falciparum 3D7 by SyBR Green method Plasmodium falciparum 2.0 nM
Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum 3D7 infected in human erythrocytes assessed as inhibition of parasite growth incubated for 72 hrs by DAPI staining based fluorescence analysis Plasmodium falciparum 0.67 nM
Antimalarial activity against CQ-sensitive Plasmodium falciparum 3D7 infected in erythrocytes by SYBR Green dye based fluorescence assay Plasmodium falciparum 9.0 nM
Antiplasmodial activity against multidrug-sensitive Plasmodium falciparum NF54 infected in human erythrocytes assessed as reduction in [3H]hypoxanthine incorporation preincubated for 48 hrs followed by [3H]hypoxanthine addition and measured after 24 hrs by liquid scintillation counting method Plasmodium falciparum 4.0 nM
Antiplasmodial activity against multidrug-resistant Plasmodium falciparum K1 infected in erythrocytes assessed as reduction in [3H]hypoxanthine incorporation preincubated for 48 hrs followed by [3H]hypoxanthine addition and measured after 24 hrs by liquid scintillation counting method Plasmodium falciparum 3.0 nM
Antimalarial activity against Plasmodium falciparum NF54 early stage (1 to 3) expressing Pfs16-LUC-GFP assessed as growth inhibition by high content imaging assay Plasmodium falciparum 2.0 nM
Antimalarial activity against Plasmodium falciparum NF54 late stage (1 to 3) expressing Pfs16-LUC-GFP assessed as growth inhibition by high content imaging assay Plasmodium falciparum 24.0 nM
Antiplasmodial activity against Plasmodium falciparum 3D7 infected in human erythrocyte assessed as intraerythrocytic growth inhibition incubated for 72 hrs by DAPI-staining based imaging analysis Plasmodium falciparum 0.6 nM
Antimalarial activity against Plasmodium falciparum NF54 assessed as inhibition of parasite growth incubated for 48 hrs by [3H]hypoxanthine incorporation assay based liquid scintillation counting method Plasmodium falciparum 6.0 nM
Antimalarial activity against Plasmodium falciparum Dd2 harbouring Pf-crt, Pf-mdrl,Pf-dhfr, Pf-dhps mutated loci assessed as inhibition of parasite growth incubated for 48 hrs by [3H]hypoxanthine incorporation assay based liquid scintillation counting method Plasmodium falciparum 6.0 nM
Antimalarial activity against Plasmodium falciparum K1 harbouring Pf-crt, Pf-mdrl,Pf-dhfr, Pf-dhps mutated loci assessed as inhibition of parasite growth incubated for 48 hrs by [3H]hypoxanthine incorporation assay based liquid scintillation counting method Plasmodium falciparum 4.0 nM
Antimalarial activity against Plasmodium falciparum 7G8 harbouring Pf-crt, Pf-mdrl,Pf-dhfr, Pf-dhps mutated loci assessed as inhibition of parasite growth incubated for 48 hrs by [3H]hypoxanthine incorporation assay based liquid scintillation counting method Plasmodium falciparum 3.0 nM
Antimalarial activity against Plasmodium falciparum TM90C2b harbouring Pf-crt, Pf-mdrl,Pfd-hfr, Pf-cytbQ0 mutated loci assessed as inhibition of parasite growth incubated for 48 hrs by [3H]hypoxanthine incorporation assay based liquid scintillation counting method Plasmodium falciparum 2.0 nM
Antimalarial activity against Plasmodium falciparum Cam3.1 harbouring Pf-crt, Pf-mdrl,Pf-dhfr, Pf-dhps, pf-kelch13 mutated loci assessed as inhibition of parasite growth incubated for 48 hrs by [3H]hypoxanthine incorporation assay based liquid scintillation counting method Plasmodium falciparum 4.0 nM
Antimalarial activity against synchronous ring stage of Plasmodium falciparum 3D7 assessed as parasite growth inhibition incubated for 72 hrs by Griffith assay based fluorescence analysis Plasmodium falciparum 0.9 nM
Antimalarial activity against synchronous ring stage of Plasmodium falciparum Dd2 assessed as parasite growth inhibition incubated for 72 hrs by Griffith assay based fluorescence analysis Plasmodium falciparum 1.3 nM

Related Entries

Cross References

Resources Reference
ChEBI 63918
ChEMBL CHEMBL361497
DrugBank DB09274
DrugCentral 247
FDA SRS 60W3249T9M
Human Metabolome Database HMDB0240267
Guide to Pharmacology 9956
PDB D95
PubChem 6917864
SureChEMBL SCHEMBL14552891
ZINC ZINC000014096305
CONTENTS